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ABSTRACT 
 
Objectives: To examine gout-related, comorbid and sociodemographic characteristics associated with 
generic and disease-specific Health-Related Quality Of Life (HRQOL) in gout.   
Methods: Adults with gout from 20 general practices were mailed a questionnaire containing the Health 
Assessment Questionnaire-Disability Index (HAQ-DI), Short-Form-36 Physical Function subscale (PF-10), 
Gout Impact Scale (GIS), and questions about gout-specific, comorbid and sociodemographic 
characteristics.  Variables associated with HRQOL were examined using multivariable linear regression 
models.   
Results: 1184 completed questionnaires were received (response 65.9%).   Worse generic and gout-
specific HRQOL was associated with frequent gout attacks (≥5 attacks PF-10 β=-4.90, HAQ-DI β=0.14, 
GIS  subscales β=8.94 to 33.26), current attack (HAQ-DI β=0.15, GIS β=-1.94 to 18.89), 
oligo/polyarticular attacks (HAQ-DI β=0.11, GIS β=0.78 to 7.86), body pain (PF-10 β=-10.68, HAQ-DI 
β=0.29, GIS β=2.61 to 11.89), anxiety (PF-10 β=-1.81, HAQ-DI β=0.06, GIS β=0.38 to 1.70), depression 
(PF-10 β=-1.98, HAQ-DI β=0.06, GIS 0.42 to 1.47) and alcohol non-consumption (PF-10 β=-16.10, HAQ-DI 
β=0.45, GIS β=4.94).  Gout-specific HRQOL was better in Caucasians than non-Caucasians (GIS β=-13.05,-
13.48). Poorer generic HRQOL was associated with diabetes mellitus (PF-10 β=-4.33, HAQ-DI β=0.14), 
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stroke (PF-10 β=-12.21, HAQ-DI β=0.37), renal failure (PF-10 β=-9.43, HAQ-DI β=0.21), myocardial 
infarction (HAQ-DI β=0.17), female gender (PF-10 β=-17.26, HAQ-DI β=0.43), deprivation (PF-10 β=-7.80, 
HAQ-DI β=0.19), and body mass index≥35kg/m2 (PF-10 β=-6.10, HAQ-DI β=0.21). 
Conclusions: HRQOL in gout is impaired by gout-specific, comorbid, and sociodemographic 
characteristics, highlighting the importance of comorbidity screening and early urate-lowering therapy.  
Both gout-specific and generic questionnaires identify the impact of disease-specific features on HRQOL 
but studies focusing on comorbidity should include generic instruments.   
INTRODUCTION 
 
Gout is the commonest inflammatory disease in the UK with a prevalence of 2.5%.[1]  Health-related 
quality of life (HRQOL) is impaired in those with gout compared to age- and sex-matched study controls, 
[2] as well as USA normative distributions.[3-5] Impairment in HRQOL in gout may be due to its disease-
specific features such as excruciatingly painful attacks, frequency of attacks, number of joints involved 
in an attack, pain in between attacks and long-term joint damage due to accumulation of tophi.[4,6-8] 
Gout is frequently associated with hypertension, renal and cardiovascular diseases as well as 
sociodemographic characteristics (age, gender, body mass index (BMI)).[9] 
HRQOL has been advocated as an important outcome domain in studies of chronic gout by the 
Outcome Measure in Rheumatology Clinical Trials (OMERACT) group [10] and can be measured using 
generic or gout-specific questionnaires.  Generic instruments have the advantage of measuring all 
important aspects of HRQOL in any population, enabling comparison across different conditions and 
interventions,[11] but may be less responsive to change in specific conditions.[12]  The generic Health 
Assessment Questionnaire Disability Index (HAQ-DI) [13] and Medical Outcomes Study Short Form 36 
(SF-36) [14] have been endorsed by the OMERACT group to measure disability and HRQOL in gout.[10] 
The more recently developed gout-specific Gout Impact Scale (GIS) measures HRQOL through 5 
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subscales (concern overall (CO), medication side-effects (MSE), unmet treatment need (UTN), wellbeing 
during attack (WBDA) and concern during attack (CDA)).[15]    
A recent systematic review highlighted that most studies of HRQOL in gout have been 
undertaken in highly-selected secondary care populations and therefore may be of limited 
generalizability to the majority of patients with gout, and few studies have included both generic and 
disease-specific measures of HRQOL.[16]  This study was therefore conducted to examine the 
association of gout, comorbid and sociodemographic characteristics with HRQOL measured using both 
generic and gout-specific questionnaires in primary care.  
METHODS 
Study design 
 
This cross-sectional study was nested within a three-year primary care-based prospective cohort study 
of HRQOL in gout.[17] Ethical approval was obtained from the North West - Liverpool East Local 
Research Ethics Committee (REC reference number: 12/NW/0297).  
 
Study population 
Potential participants were identified from the primary care electronic medical records of adults aged ≥ 
18 years registered with 20 general practices within the West Midlands, UK by a diagnostic Read code 
for gout or a prescription for colchicine or allopurinol during the preceding two years.  Read Codes are 
used to code clinical data in primary care in the UK.[18]  
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Data collection 
 
Eligible participants were mailed a questionnaire which included consent for both further contact and 
medical record review.  Non-responders were sent a reminder postcard after 2 weeks, followed by a 
repeat questionnaire after a further 2 weeks. 
The following gout-specific variables were ascertained from the questionnaire: whether 
currently experiencing an attack, number of attacks experienced in the preceding 12 months, history of 
oligo or polyarticular attacks, age at diagnosis, and treatment with allopurinol.  Serum urate (SUA) levels 
and the presence of tophi were ascertained from the medical records of consenting participants.  
Where SUA was recorded, the highest value of the SUA in the preceding two years was used. 
The questionnaire asked participants if they had ever been diagnosed as having or been treated 
for the following medical comorbidities: diabetes mellitus, stroke, transient ischaemic attack (TIA), 
hypertension, hyperlipidaemia, myocardial infarction (MI), angina, renal failure, and renal calculi. 
Participants were asked to shade the location of body pain experienced in the last month and lasting at 
least one day on a body manikin.[19] Anxiety was ascertained using the Generalised Anxiety Disorder-7 
(GAD-7) questionnaire  and depression using the Patient Health Questionnaire-9 (PHQ-9).[20,21]  
The questionnaire also asked about sociodemographic characteristics: frequency of alcohol 
consumption, ethnicity, relationship status, attendance at a further education institution, and self-
reported height and weight.  Age, gender and Multiple Deprivation Indices (MDI) ranks based on area 
postcodes were available from the general practice records. 
HRQOL was measured using the SF-36 physical functioning subscale (PF-10),[14] HAQ-DI,[13] 
and the five sub-scales of the GIS.[15] Higher scores in the HAQ-DI (range 0 to 3) and GIS (range 0-100) 
indicate more activity limitation and higher impact of gout respectively.[13,15] Lower scores for the PF-
10 (range 0 to 100) indicate greater functional limitation.[14] The PF-10 asks responders to rate 
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limitation at the time of questionnaire completion [14] and the HAQ-DI over the past one week [13].  
The GIS assess the impact of gout at the time of questionnaire as well as during the last gout attack. [15]  
Statistical analysis 
 
Gout, co-morbid, and socio-demographic characteristics and HRQOL scores of responders were 
described using simple descriptive statistics: frequency and percentage for categorical variables and 
mean (SD) or median (IQR) for continuous variables, depending upon the distribution of the variables.   
Disease duration (current age minus age at diagnosis) was categorised into four ten-year bands: 
0-9, 10-19, 20-29 and ≥30 years. SUA was dichotomised into values above and below the 
internationally-agreed target SUA level for urate-lowering therapy, ≤360μmol/L  and >360 μmol/L. [44, 
45]  GAD-7 scores for anxiety, PHQ-9 scores for depression  (both ranging from none to severe) and BMI 
calculated from self-reported height and weight (underweight to obese) were categorised using 
previously validated cut-off points.[20-22] Relationship status was classified as married/co-habiting and 
others (separated, divorced, widowed or single). Owing to the small number of non-Caucasian 
participants, ethnicity was classified as Caucasian and non-Caucasian. The MDI rankings were split into 
quintiles (most deprived, second most deprived, mid deprived, second least deprived and least 
deprived). HRQOL scores were left unchanged as continuous interval scales based on the assumption 
that there is an underlying continuum of functional limitation, disability and impact of gout in the PF-10, 
HAQ-DI and GIS respectively. 
Unadjusted associations of gout, co-morbid and socio-demographic characteristics with HRQOL 
were assessed through a series of linear regression models.  Subsequently, to obtain adjusted 
associations, a full multivariable model was fitted, including gout characteristics (frequency of attack, 
currently having a gout attack, history of oligo/polyarticular attacks, treatment with allopurinol, disease 
duration), co-morbid (diabetes mellitus, stroke, hypertension, TIA, hyperlipidaemia, renal failure, MI, 
renal calculi, angina, body pain, anxiety, depression) and socio-demographic factors (age, gender, MDI, 
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ethnicity, BMI, further education, alcohol frequency, relationship status).  Results are presented as β 
coefficient with 95% confidence interval (CI).  In order to include the maximum number of participants 
in the regression models, pairwise deletion was selected during regression analysis.  All statistical 
analyses were conducted using SPSS (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM 
Corp).   
 
Missing data 
 
When not recorded in the medical notes, tophi were considered absent and SUA was assumed to not 
have been measured.  Owing to the low prevalence of tophi (2.4%) and frequency of missing data for 
SUA (57% missing), these variables were excluded from multivariable analyses. The percentage of 
missing data for other variables was low, with ≤ 10% for all gout, co-morbid, socio-demographic and 
HRQOL variables, except for ‘miss work because of symptoms’ in the GIS WBDA sub-scale and for ‘taking 
a bath’ in the HAQ-DI which had 13.6% and 15.5% missing values respectively.  In order to assess the 
possible impact of missing data on multivariable associations, multiple imputation by chained equations 
(MICE) [23] was used to impute missing data (using STATA v14.2 for Windows) on frequency of attacks, 
history of oligo or polyarticular attacks, and HRQOL.  Neither β coefficients nor their standard errors 
changed considerably following analysis based on ten sets of multiply imputed data. It was therefore 
deemed unnecessary to impute for missing data in other variables.   
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RESULTS 
 
Study population 
 
Of 1805 potential participants, 1796 were suitable for mailing (nine were excluded due to ill-health, 
death or departure from the general practice). Of these, 1184 returned a completed questionnaire 
(response 65.9%). As previously reported, responders were older, and more likely to be male and live in 
less deprived areas than non-responders.[24] Consent to medical record review was given by 1079 
baseline respondents (91.9%).  
 
Responder characteristics 
 
Mean (SD) age of responders was 65.6 years (12.5); 990 (83.6%) were male and 1126 (97.6%) were 
Caucasian (Table 1).  The median number (IQR) of acute gout attacks over the preceding 12 months was 
1 (1-3), with 398 participants (35.4%) reporting no attacks during this time-period. Mean disease 
duration was 16.8 years (SD 21.1). Six-hundred and thirty participants (56.3%) reported currently 
receiving allopurinol 
 
Mean HRQOL scores 
 
The overall mean (SD) scores for HAQ-DI was 0.51 (0.71) and PF-10 was 75.86 (26.12).  Mean (SD) 
HRQOL scores measured using the GIS sub-scales were: CO: 48.65 (28.33), MSE: 40.45 (26.33), UTN: 
33.46 (20.57), WBDA: 45.19 (26.41), CDA: 40.13 (24.35).   
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The association between HRQOL and gout, co-morbid and socio-demographic characteristics 
Gout characteristics 
 
In unadjusted analyses, HRQOL measured using the PF-10, HAQ-DI and GIS was poorer in those 
currently having an attack of gout compared to those not having an attack (all GIS subscales), in those 
with a history of oligo/polyarticular attacks compared to those with only monoarticular attacks (all GIS 
subscales except UTN), and higher frequency of attacks in the past 12 months (Tables 2 and 3). People 
currently treated with allopurinol had worse HRQOL (HAQ-DI), lower unmet treatment need but greater 
impact of gout on well-being during an attack than those untreated. Tophi were associated with worse 
HRQOL measured using the HAQ-DI only.  SUA >360µmol/L was associated with worse HRQOL 
measured using the GIS CO, MSE, UTN and CDA only. Longer gout duration was associated with better 
HRQOL measured using the GIS CO, MSE, UTN and CDA. 
After adjustment for comorbid and sociodemographic characteristics, poor HRQOL was 
independently associated with more frequent attacks (PF-10, HAQ-DI, and GIS CO, MSE, UTN, and CDA), 
having a current attack (HAQ-DI and GIS CO, MSE, UTN and CDA), and a history of oligo/polyarticular 
attacks (HAQ-DI and GIS CO, MSE, WBDA and CDA). Compared to those with the shortest gout duration 
(0-9 years), lower unmet treatment need was seen in the middle gout duration categories (10-19 years, 
20-29 years) but not those with longest duration (>30 years).  People treated with allopurinol had lower 
unmet treatment need but greater impact of gout on well-being during an attack than those untreated 
(Table 3). 
Co-morbidities 
 
In unadjusted analyses, HRQOL measured using the PF-10 and HAQ-DI was poorer in the presence 
(compared to the absence) of diabetes mellitus, stroke, hypertension, hyperlipidaemia (HAQ-DI only), 
renal failure, MI, angina, body pain, and anxiety and depression (Table 2). Poorer HRQOL measured 
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using the GIS was seen in the absence of hypertension (CO) and TIA (CO, WBDA), and in the presence of 
renal calculi (MSE), body pain (all sub-scales), anxiety (all) and depression (all) (Table 3).  
After adjustment for gout-related and sociodemographic characteristics, poor HRQOL measured 
using the PF-10 and HAQ-DI was independently associated with diabetes mellitus, stroke, renal failure, 
MI (HAQ-DI only), angina, body pain, anxiety and depression (Table 2). The absence of hypertension 
(CO) and presence of body pain (CO, MSE, WBDA and CDA), anxiety (all) and depression (all) remained 
independently associated with HRQOL measured using the GIS (Table 3).  
 
Socio-demographic characteristics 
 
In unadjusted analyses, older age was associated with poorer HRQOL measured using the PF-10 and 
HAQ-DI but better HRQOL measured using the GIS (CO, MSE, WBDA, CDA) (Table 4, Table 5). HRQOL 
was poorer in females (PF-10, HAQ-DI, GIS UTN), the severely obese (PF-10, HAQ-DI and GIS CO, MSE, 
and CDA), and those in the most deprived neighbourhood deprivation quintile (PF-10, HAQ-DI, all GIS 
subscales except UTN), of non-Caucasian ethnicity (GIS CO, MSE, WBDA, CDA), who did not attend 
further education (PF-10, HAQ-DI and GIS MSE, UTN and CDA), and those not married/cohabiting (PF-
10, HAQ-DI, GIS CDA). Compared with those who drank alcohol daily, infrequent/non-drinkers had 
worse HRQOL (PF-10, HAQ-DI, all GIS sub-scales).  
After adjustment for gout-related and comorbid characteristics, the associations between older 
age and poorer HRQOL measured with the PF-10 and HAQ-DI but better HRQOL measured using the GIS 
(CO, MSE, WBDA, CDA) remained (Table 4, Table 5).  Female gender (PF10, HAQ-DI), neighbourhood 
deprivation (PF-10, HAQ-DI), non-Caucasian ethnicity (GIS MSE and CDA), severe obesity (PF-10, HAQ-
DI), non-attendance at further education (PF-10), infrequent/non-consumption of alcohol (PF-10, HAQ-
DI, GIS WBDA) and being unmarried/not cohabiting (PF-10) remained independently associated with 
poor HRQOL
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DISCUSSION 
 
This large primary care-based cross-sectional survey assessed HRQOL using generic and specific 
instruments in patients with gout.  We found that poor HRQOL in gout was associated with a range 
of gout-specific (frequency of attacks, having a current attack, history of oligo/polyarticular attacks 
and treatment with allopurinol), co-morbid (diabetes mellitus, stroke, renal failure, angina, 
generalised body pain, anxiety and depression) and socio-demographic characteristics (older age, 
female gender, deprivation, ethnicity, obesity, infrequent alcohol consumption and marital status).  
In general, the generic instruments identified associations between poor HRQOL and gout, co-
morbid and sociodemographic characteristics whereas the gout-specific GIS found associations 
between poor HRQOL and gout characteristics but not comorbidities (other than anxiety, depression 
and body pain) or sociodemographic characteristics (except age, ethnicity and alcohol intake).  
This is the first UK primary care-based cross-sectional study of both generic and disease-
specific HRQOL in gout in a large unselected gout sample, ensuring the results are highly 
generalizable. It is likely that those being treated with allopurinol have more severe gout than those 
untreated.  Although treatment with allopurinol was associated with lower unmet treatment need, it 
was also associated with higher concerns about well-being during an acute attack.  These findings 
contrast with two previous primary care-based studies in the UK and Mexico where treatment with 
allopurinol had no effect on HRQOL.[2,8] The difference in findings of these studies may be 
attributed to methods of gout case ascertainment (clinical assessment, use of Wallace criteria [25]), 
small sample sizes and use of generic instruments only.  Better HRQOL in those who drink alcohol 
compared to those who do not is also a novel observation in gout.  Possible underlying mechanisms 
include the effect of alcohol to enhance release of gamma-amino butyric acid (which alters pain 
perception in chronic pain),[26-28] as a stress reliever, and to promote social integration, all of 
which may lead to an improvement in HRQOL.[28] The lack of association between HRQOL and tophi 
(PF-10, GIS) is also worthy of discussion.  Previous studies which used the SF-12 and Health 
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Assessment Questionnaire found associations between tophi and poor HRQOL [7,8] whereas 
another study found tophi to be associated with greater unmet treatment need but not gout impact 
on the other GIS sub-scales.[29] This may be explained by differences in sampling frame, the use of 
different instruments to measure HRQOL, low frequency of tophi (2.4%) in primary care records 
possibly due to under-recognition/recording or misdiagnosis, and a time-lag between entry of tophi 
in the medical record and completion of study questionnaires in our study.   An unexpected finding 
of our study was that HRQOL was worse in older participants compared to younger participants 
when measured with the generic instruments (PF-10, HAQ-DI) but disease-specific HRQOL (GIS CO, 
MSE, WBDA, CDA) was better in older people. It is plausible that as people age, accumulated 
comorbidity has greater impact than gout on HRQOL. The associations of poorer HRQOL with female 
gender due to greater disease and co-morbid severity,[30,31] frequency of attacks and history of 
oligo/polyarticular attacks in this study have been reported previously.[2,4,7,32]  
  
The strengths of this study are the high response, the primary care setting ensuring generalizability 
to the majority of patients with gout who are managed exclusively in primary care, and the use of 
both generic and disease-specific measures of HRQOL.  Independent association of selected co-
morbidities was examined based upon their well-recognised association with gout (metabolic 
syndrome, renal failure, vascular disease).[9] Although it is recognised that those with gout 
experience pain, isolation and stigmatisation [33] and the prevalence of depression in gout ranges 
from 13.5% to 20%,[34,35] there have been no other studies that have examined the association of 
anxiety and depression in gout with HRQOL, which is clearly demonstrated in this study.  A number 
of caveats are worthy of acknowledgement. Although this is the first study to use both generic and 
gout-specific measures of HRQOL in a primary care population, it is important to acknowledge that 
the GIS has not yet been fully endorsed by OMERACT owing to concerns regarding its construct 
validity.[36] However, it has good content and face validity, test-retest reliability and 
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responsiveness.[16] The pre-dominantly Caucasian population reflects the demographic composition 
of the area surveyed.  Lower response from deprived neighbourhoods may arise from low health 
literacy, disengagement [37] and social desirability bias.[38] Participant-reported prescription of 
allopurinol in this study was higher than that reported in other UK primary care studies [1,2,39] 
suggesting that participants may have had more severe gout than non-respondents, reflecting 
possible unmeasured response bias. Although the identification of gout cases was based upon Read 
codes without ascertainment of the method of diagnosis, Read code diagnosis of gout has been 
validated previously with a positive predictive value of 90%.[40] Primary care medical record free-
text entries describing features of inflammation and the joints affected are shown to be concordant 
with a diagnosis of gout[41] but there may be some people who have been misclassified as gout but 
were still included in the study.  
 The participating practices in this study undergo regular audits to ensure adequate quality and 
completeness of data entry.[42] However using medical records alone to identify people with gout 
cases may have failed to ascertain people who did not consult or in whom the diagnosis was not 
recorded.   
 
The main implications of our findings are that primary care clinicians should be aware that gout and 
co-existing comorbidities are associated with poor HRQOL. Our findings add weight to the argument 
that people with gout should be offered ULT early in the course of disease to prevent poor HRQOL 
associated with recurrent attacks and therefore progressive disease.  Whilst our finding that 
comorbidities associated with poor HRQOL supports the recommendation of current guidelines to 
screen for and treat associated physical comorbidities,[43,44] our study highlights the importance of 
psychological comorbidities (anxiety and depression) in gout. 
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A recent systematic review identified only five prospective studies of HRQOL in gout demonstrating 
a need for prospective studies to examine the natural history of HRQOL in gout and determine 
predictors of outcome including treatment.[16]  Studies evaluating the impact of gout as well as 
medical comorbidities may benefit from using generic questionnaires whereas those that assess the 
impact of gout and psychological co-morbidities may use the GIS. However, a combination of both 
generic and disease-specific questionnaires is likely to provide the most comprehensive overview of 
the role of gout and other associated factors in HRQOL.   
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Table 1: Characteristics of the survey responders 
Variable  
Age (years), mean (SD) 65.6 (12.5) 
Male 990 (83.6) 
Married or cohabiting 882 (75.7) 
Attended further education 249 (22.3) 
Ethnicity - Caucasian 1126 (97.6) 
BMI (kg/m2)  
 <25 
25-29.9 
30-34.9 
≥35 
230 (20.4) 
511 (45.3) 
260 (23.1) 
127 (11.3) 
Gout characteristics  
Attack frequency in the past 12 months  
 0 
1 
2 
3 
4 
≥5 
398 (35.4) 
231 (20.6) 
187 (16.7) 
103 (9.2) 
67 (6.0) 
137 (12.2) 
Currently having an attack of gout 132 (11.6) 
History of oligo/polyarticular attacks 436 (38.6) 
Treatment with allopurinol 630 (56.3) 
Tophi 25 (2.4) 
Serum uric acid, mean (SD)a 441.4 (115.5) 
Disease duration (years)  
 0-9 
10-19 
20-29 
≥30 
598 (56.6) 
248 (23.5) 
141 (13.3) 
70 (6.6) 
Co-morbid conditions  
Hypertension 731 (61.7) 
Body painb 651 (67.2) 
Hyperlipidaemia 508 (42.9) 
Diabetes mellitus 205 (17.3) 
Angina 147 (12.4) 
Myocardial infarction 119 (10.1) 
Renal calculi 81 (6.8) 
Transient ischaemic attack 62 (5.2) 
Renal failure 56 (4.7) 
Stroke 37 (3.1) 
GAD7 score, mean (SD) 2.8 (4.5) 
PHQ9 score, mean (SD) 3.6 (5.2) 
Alcohol intake frequency  
 Daily 273 (23.4) 
 3-4 times per week 263 (22.5) 
 1-2 times per week 254 (21.8) 
 1-3 times per month 109 (9.3) 
 Special occasions 155 (13.3) 
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 Never 113 (9.7) 
Values are n (%) unless otherwise stated.  BMI, body mass index; GAD-7, Generalised Anxiety 
Disorder-7 questionnaire; PHQ-9, Patient Health Questionnaire-9; SD, Standard Deviation; SUA, 
Serum Uric Acid 
a sUA available for 461 of 1079 participants consenting to medical record review (43%) 
b pain experienced in the last month and lasting at least one day shaded on a body manikin 
 
Table 2 Linear regression association of HRQOL measured using the PF-10 and HAQ-DI with gout 
and co-morbid characteristics 
Characteristics PF-10  (β (95%CI)) HAQ-DI (β (95%CI)) 
Unadjusted Adjusted Unadjusted Adjusted 
Gouta     
Number of attacks in 
last year 
    
 0 
1 
2 
3 
4 
≥5 
0.0 
0.70 (-3.77, 5.18)  
-4.94 (-9.72, -
0.15) 
-6.18 (-12.41, 
0.04) 
-13.51 (-20.73, -
6.29) 
-18.10 (-23.67, -
12.53) 
0.0 
-0.76 (-4.03, 
2.52) 
-2.6 (-6.33, 
1.00) 
-2.37 (-7.56, 
2.82) 
0.13 (-5.44, 
5.70) 
-4.90 (-9.36, -
0.45) 
0.0 
0.01 (-0.10, 
0.13) 
0.11 (-0.01, 
0.23) 
0.08 (-0.07, 
0.24) 
0.32 (0.13, 0.50) 
0.48 (0.34, 0.62) 
0.0 
0.03 (-0.07, 
0.13) 
0.06 (-0.05, 
0.17) 
-0.02 (-0.17, 
0.12) 
-0.10 (-0.25, 
0.06) 
0.14 (0.01, 
0.27) 
Current gout attack -14.30 (-19.67, -
8.93) 
-4.20 (-8.48, 
0.07) 
0.41 (0.28, 0.54) 0.15 (0.04, 
0.27) 
Oligo/polyarticular 
attacks 
-8.96 (-12.34, -
5.59) 
-1.65 (-4.30, 
1.01) 
0.28 (0.20, 0.37) 0.11 (0.03, 
0.18) 
Treatment with 
allopurinol 
-1.55 (-4.91, 
1.81) 
-1.43 (-4.01, 
1.15) 
0.12 (0.03, 0.20) 0.06 (-0.02, 
0.13) 
Disease duration (years)     
 0-9 
10-19 
20-29 
≥30 
0.0 
2.05 (-2.21, 6.30) 
1.96 (-3.31, 7.23) 
-0.90 (-8.00, 
6.20) 
0.0 
1.80 (-1.51, 
5.11) 
1.59 (-2.36, 
5.54) 
0.70 (-4.89, 
6.28) 
0.0 
-0.02 (-0.13, 
0.08) 
-0.01 (-0.14, 
0.12) 
0.11 (-0.07, 
0.29) 
0.0 
-0.02 (-0.12, 
0.07) 
-0.05 (-0.16, 
0.07) 
0.03 (-0.13, 
0.19) 
Serum uric acid >360 
μmol/L 
0.00 (-0.01, 0.01) - 0.00 (-0.00, 
0.00) 
- 
Tophi -7.61 (-18.47, 
3.24) 
- 0.30 (0.02, 0.58) - 
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Characteristics PF-10  (β (95%CI)) HAQ-DI (β (95%CI)) 
Unadjusted Adjusted Unadjusted Adjusted 
    
Comorbidityb    
Diabetes mellitus -11.43 (-15.76, -
7.10) 
-4.32 (-8.51, -
0.10) 
0.35 (0.25, 0.46) 0.14 (0.03, 
0.25) 
Stroke -17.97 (-27.73, -
8.20) 
-12.19 (-21.18, 
-3.21) 
0.53 (0.29, 0.76) 0.37 (0.13, 
0.60) 
Hypertension -8.13 (-11.47, -
4.79) 
-1.20 (-4.58, 
2.17) 
0.21 (0.13, 0.30) -0.02 (-0.11, 
0.06) 
Transient ischaemic 
attack 
-0.24 (-7.91, 
7.43) 
-1.54 (-8.67, 
5.59) 
-0.03 (-0.22, 
0.16) 
0.04 (-0.14, 
0.22) 
Hyperlipidaemia -3.05 (-6.40, 
0.31) 
-0.03 (-3.14, 
3.07) 
0.09 (0.01, 0.18) -0.02 (-0.10, 
0.06) 
Renal failure -19.25 (-27.34, -
11.15) 
-9.45 (-17.36, -
1.54) 
0.56 (0.37, 0.75) 0.21 (0.01, 
0.41) 
Myocardial infarction -12.18 (-17.78, -
6.58) 
-5.33(-10.80, 
0.14) 
0.30 (0.17, 0.44) 0.17 (0.03, 
0.31) 
Renal calculi 1.54 (-5.46, 8.54) 2.90 (-3.45, 
9.25) 
0.15 (-0.02, 
0.31) 
0.03 (-0.12, 
0.19) 
Angina -17.08 (-22.13, -
12.04) 
-10.35 (-15.30, 
-5.42) 
0.42 (0.29, 0.54) 0.23 (0.10, 
0.35) 
Body pain -17.57 (-21.08, -
14.06) 
-10.68 (-14.07, 
-7.29) 
0.45 (0.36, 0.54) 0.29 (0.20, 
0.38) 
Anxiety -2.24 (-2.58, -
1.89) 
-1.81 (-2.14, -
1.47) 
0.06 (0.05, 0.07) 0.06 (0.05, 
0.07) 
Depression -2.52 (-2.79, -
2.26) 
-1.98 (-2.24, -
1.71) 
0.07 (0.07, 0.08) 0.06 (0.05, 
0.07) 
CI, confidence interval; HAQ-DI, Health Assessment Questionnaire-Disability Index; PF-10, Physical 
Function-10 
a Adjusted for comorbid and socio-demographic characteristics; b Adjusted for gout-related and 
socio-demographic characteristics. Values in bold indicate statistically significant associations 
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Table 3 Linear regression association of HRQOL measured using the Gout Impact Scale with gout 
and comorbid characteristics 
 GIS CO (β 
(95%CI)) 
GIS MSE (β 
(95%CI)) 
GIS UTN(β 
(95%CI)) 
GIS WBDA (β 
(95%CI)) 
GIS CDA (β 
(95%CI)) 
Unadjus
ted  
Adjust
ed 
Unadjus
ted  
Adjust
ed  
Unadjus
ted  
Adjust
ed  
Unadjus
ted  
Adjust
ed  
Unadjus
ted  
Adjust
ed  
Gout
a
           
Number of 
attacks in last 
year 
          
 0 
1 
 
2 
 
3 
 
4 
 
≥5 
0.0 
9.80 
(5.79, 
13.81) 
20.34 
(16.01, 
24.66) 
28.22 
(22.89, 
33.54) 
32.70 
(26.37, 
39.03) 
41.99 
(37.16, 
46.83) 
0.0 
10.49 
(6.00, 
14.97) 
17.10 
(12.01
, 
22.19) 
27.49 
(20.82
, 
34.16) 
25.23 
(17.92
, 
32.55) 
33.29 
(27.33
, 
39.24) 
0.0 
0.76 
(-3.39, 
4.92) 
8.55 
(4.08, 
13.02) 
17.36 
(11.86, 
22.85) 
17.85 
(11.18, 
24.53) 
21.90 
(16.90, 
26.90) 
0.0 
-1.51 
(-6.16, 
3.15) 
1.76 
(-3.47, 
6.99) 
15.79 
(8.89, 
22.70) 
6.58 
(-1.00, 
14.17) 
8.92 
(2.78, 
15.06) 
0.0 
12.13 
(8.92, 
15.34) 
12.77 
(9.35, 
16.19) 
13.39 
(9.16, 
17.63) 
13.34 
(8.28, 
18.41) 
23.97 
(20.13, 
27.82) 
0.0 
11.52 
(7.90, 
15.14) 
13.52 
(9.47, 
17.57) 
15.05 
(9.69, 
20.42) 
13.71 
(7.85, 
19.56) 
22.90 
(18.14
, 
27.67) 
0.0 
-0.013 
(-4.39, 
4.13) 
4.20 
(-0.40, 
8.80) 
3.86 
(-1.84, 
9.56) 
12.73 
(5.98, 
19.48) 
14.35 
(9.22, 
19.48) 
0.0 
-1.00 
(-5.49, 
3.49) 
-0.07 
(-5.16, 
5.01) 
0.84 
(-5.84, 
7.52) 
-0.42 
(-7.74, 
6.90) 
-2.40 
(-8.37, 
3.56) 
0.0 
3.24 
(-0.60, 
7.07) 
10.72 
(6.58, 
14.85) 
12.08 
(7.00, 
17.16) 
18.85 
(12.74, 
24.97) 
21.02 
(16.41, 
25.64) 
0.0 
2.65 
(-
1.369, 
6.70) 
6.51 
(1.92, 
11.10) 
8.52 
(2.52, 
14.53) 
6.12  
(-0.46, 
12.71) 
10.67 
(5.29, 
16.06) 
Current gout 
attack 
26.27 
(21.23, 
31.30) 
18.71 
(12.77
, 
24.67) 
17.79 
(12.90, 
22.69) 
11.27 
(5.46, 
17.09) 
18.89 
(15.11, 
22.67) 
17.79 
(13.18
, 
22.38) 
6.93 
(2.08, 
11.79) 
-1.94 
(-7.43, 
3.55) 
11.71 
(7.25, 
16.17) 
5.75 
(0.77, 
10.74) 
Oligo/polyartic
ular attacks 
16.01 
(12.70, 
19.32) 
7.86  
(3.95, 
11.77) 
13.87 
(10.76, 
16.98) 
7.42 
(3.70, 
11.14) 
2.18 
(-0.37, 
4.72) 
0.78 
(-2.29, 
3.85) 
14.16 
(11.06, 
17.26) 
6.69 
(3.17, 
10.22) 
11.20 
(8.31, 
14.10) 
4.83 
(1.81, 
8.06) 
Treatment 
with 
allopurinol 
-2.65 
(-6.05, 
0.76) 
-2.63 
(-6.48, 
1.23) 
0.23 
(-2.96, 
3.42) 
0.07 
(-3.59, 
3.74) 
-11.55 
(-13.99, 
-9.12) 
-10.56 
(-
13.47, 
-7.65) 
5.13 
(1.97, 
8.29) 
5.25 
(1.79, 
8.70) 
2.40 
(-0.53, 
5.34) 
1.96 
(-1.22, 
5.14) 
Disease 
duration 
(years) 
          
 0-9 
10-19 
 
20-29 
 
≥30 
0.0 
-1.19 
(-5.44, 
3.07) 
-6.87 
(-12.09, 
-1.64) 
-8.96 
(-16.01, 
-1.92) 
0.0 
-2.63 
(-7.44, 
2.18) 
-3.86 
(-9.68, 
1.97) 
-3.12 
(-
11.30, 
5.06) 
0.0 
1.17 
(-2.79, 
5.13) 
-0.43 
(-5.30, 
4.44) 
-7.65 
(-14.21, 
-1.09) 
0.0 
0.18 
(-4.40, 
4.69) 
1.49 
(-4.01, 
6.99) 
-7.39 
(-
15.11, 
0.33) 
0.0 
-3.97 
(-7.08, -
0.86) 
-9.34 
(-13.13, 
-5.55) 
-4.07 
(-9.17, 
1.02) 
0.0 
-5.76 
(-9.46, 
-2.05) 
-8.20 
(-
12.67, 
-3.74) 
-1.91 
(-8.17, 
4.35) 
0.0 
2.39 
(-1.57, 
6.35) 
-1.63 
(-6.52, 
3.27) 
-3.16 
(-9.81, 
3.48) 
0.0 
1.99 
(-2.34, 
6.32) 
1.26 
(-4.01, 
6.53) 
-2.08 
(-9.44, 
5.29) 
0.0 
0.99 
(-2.68, 
4.66) 
-1.07 
(-5.61, 
3.46) 
0.92 
(-5.17, 
7.01) 
0.0 
0.61 
(-3.33, 
4.55)  
0.32 
(-4.47, 
5.10) 
0.23 
(-6.47, 
6.93) 
Tophi -3.00  
(-14.21, 
8.22) 
- 6.15 
(-4.43, 
16.73) 
- 5.47 
(-2.76, 
13.71) 
- -4.67 
(-15.25, 
5.91) 
- -0.44 
(-10.02, 
9.15) 
- 
Serum uric 
acid >360 
μmol/L 
0.02 
(0.01, 
0.03) 
- 0.01 
(0.01,0.
02) 
- 0.01 
(0.00, 
0.02) 
- 0.01 
(-0.00, 
0.01) 
- 0.01 
(0.00, 
0.01) 
- 
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 GIS CO (β (95%CI)) GIS MSE (β 
(95%CI)) 
GIS UTN (β 
(95%CI)) 
GIS WBDA (β 
(95%CI)) 
GIS CDA (β 
(95%CI)) 
Unadjus
ted  
Adjust
ed  
Unadjus
ted  
Adjust
ed  
Unadjus
ted  
Adjust
ed  
Unadjus
ted 
Adjust
ed  
Unadjus
ted 
Adjust
ed 
Comorbidity
b
 
          
Diabetes 
mellitus 
-3.18  
(-7.50, 
1.15) 
1.22 
(-3.04, 
5.49) 
-4.27 
(-8.32 -
0.22) 
-2.45 
(-6.90, 
2.00) 
0.76 
(-2.44, 
3.97) 
2.15 
(-1.26, 
5.55) 
-0.60 
(-4.64, 
3.43) 
-1.09 
(-5.52, 
3.34) 
0.16 
(-3.57, 
3.88) 
-0.54 
(-4.61, 
3.53) 
Stroke -2.85 
(-12.39, 
6.70) 
-5.20 
(-
14.55, 
4.17) 
-4.94 
(-13.93, 
4.05) 
-3.07 
(-
12.97, 
6.82) 
-4.18 
(-11.21, 
2.85) 
-3.84 
(-
11.34, 
3.66) 
-6.53 
(-15.42, 
2.36) 
-8.18 
(-
17.95, 
1.59) 
-0.25 
(-8.57, 
8.07) 
1.25 
(-7.72, 
10.21) 
Hypertensio
n 
-4.03 
(-7.41, -
0.65) 
-3.50 
(-6.94, 
-0.06) 
-1.20 
(-4.37, 
1.98) 
-0.58 
(-4.17, 
3.02) 
-0.42 
(-2.93, 
2.08) 
0.87 
(-1.88, 
3.63) 
-1.65 
(-4.80, 
1.50) 
-0.47 
(-4.05, 
3.11) 
-0.15 
(-3.08, 
2.77) 
-0.83 
(-4.13, 
2.47) 
Transient 
ischaemic 
attack 
-8.49 
(-15.73, -
1.24) 
-4.80 
(-
11.91, 
2.30) 
-5.07 
(-11.87, 
1.71) 
-2.00 
(-9.45, 
5.46) 
-4.10 
(-9.45, 
1.25) 
-2.26 
(-7.96, 
3.44) 
-7.70 
(-14.51, -
0.90) 
-4.92 
(-
12.41, 
2.57) 
-4.17 
(-10.41, 
2.07) 
0.09 
(-6.72, 
6.89) 
Hyperlipidae
mia 
-0.45 
(-3.76, 
2.87) 
1.23 
(-1.94, 
4.39) 
0.04 
(-3.07, 
3.15) 
0.55 
(-2.75, 
3.86) 
-0.34 
(-2.80, 
2.10) 
0.68 
(-1.85, 
3.21) 
-0.27 
(-3.36, 
2.82) 
-0.44 
(-3.74, 
2.86) 
0.91 
(-1.95, 
3.77) 
0.24  
(-2.79, 
3.28) 
Renal failure 10.56 
(2.76, 
18.36) 
3.17 
(-4.89, 
11.23) 
5.26 
(-1.88, 
12.39) 
2.68 
 (-5.46, 
10.83) 
-0.21 
(-5.80, 
5.37) 
-1.03 
(-7.21, 
5.14) 
5.13 
(-2.09, 
12.35) 
1.90 
(-6.41, 
10.21) 
5.86 
(-0.79, 
12.52) 
0.75 
(-6.86, 
8.36) 
Myocardial 
infarction 
-2.89 
(-8.37, 
2.60) 
-1.79 
(-7.24, 
3.67) 
0.25 
(-4.85, 
5.36) 
-0.94 
(-6.60, 
4.72) 
1.03 
(-3.01, 
5.07) 
2.20 
(-2.12, 
6.51) 
-1.38 
(-6.45, 
3.70) 
-0.59 
(-6.25, 
5.06) 
1.64 
(-3.07, 
6.36) 
1.48 
(-3.74, 
6.70) 
Renal calculi 5.30 
(-1.25, 
11.86) 
2.30 
(-3.79, 
8.38) 
7.84 
(1.80, 
13.89) 
6.05 
(-0.24, 
12.34) 
2.60 
(-2.17, 
7.36) 
0.90 
(-3.90, 
5.69) 
-1.11 
(-7.12, 
4.90) 
-4.69 
(-
10.96, 
1.58) 
4.75 
(-0.88, 
10.38) 
2.33 
(-3.48, 
8.15) 
Angina -1.47 
(-6.48, 
3.55) 
-0.10 
(-5.06, 
4.85) 
-0.26 
(-4.89, 
4.38) 
0.83 
(-4.29, 
5.94) 
1.73 
(-1.92, 
5.38) 
1.36 
(-2.53, 
5.26) 
1.66 
(-2.96, 
6.28) 
2.21 
(-2.94, 
7.36) 
3.40 
(-0.89, 
7.70) 
2.85 
(-1.85, 
7.56) 
Body pain 16.10 
(12.39, 
19.81) 
9.35 
(5.70, 
13.00) 
12.20 
(8.67, 
15.71) 
9.41 
(5.59, 
13.24) 
6.58 
(3.77, 
9.39) 
2.61 
(-0.36, 
5.58) 
12.79 
(9.33, 
16.24) 
11.89 
(8.11, 
15.66) 
11.10 
(7.86, 
14.34) 
7.32 
(3.82, 
10.83) 
Anxiety 1.78 
(1.41, 
2.14) 
0.88 
(0.50, 
1.26) 
1.52 
(1.19, 
1.86) 
1.11 
(0.72, 
1.50) 
0.63 
(0.36, 
0.90) 
0.38 
(0.08, 
0.68) 
1.83 
(1.49, 
2.16) 
1.44 
(1.05, 
1.82) 
2.010 
(1.81, 
2.40) 
1.70 
(1.36, 
2.05) 
Depression 1.59 
(1.27, 
1.91) 
0.84 
(0.50, 
1.19) 
1.37 
(1.08, 
1.67) 
1.07 
(0.72, 
1.42) 
0.58 
(0.35,0.8
2) 
0.42 
(0.16, 
0.69) 
1.72 
(1.43, 
2.01) 
1.47 
(1.13, 
1.82) 
1.81 
(1.55, 
2.07) 
1.47 
(1.16, 
1.78) 
CDA, Concern During Attack; CI, Confidence Interval; CO, Concern Overall; GIS, Gout Impact Scale; MSE, Medication Side 
Effects; UTN, Unmet Treatment Need; WBDA, Wellbeing during attack 
a
 Adjusted for comorbid and socio-demographic characteristics; 
b
 Adjusted for gout-related and sociodemographic 
characteristics.  Values in bold represent statistically significant associations 
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Table 4 Linear regression association of HRQOL measured using the PF-10 and HAQ-DI with 
sociodemographic characteristics 
 PF-10  (β (95%CI)) HAQ-DI (β (95%CI)) 
Unadjusted Adjusteda Unadjusted Adjusteda 
Age -0.69 (-0.82, -
0.57) 
-0.53 (-0.66, -
0.41) 
0.02 (0.01, 
0.02) 
0.02 (0.01, 
0.02) 
Female Gender -21.41 (-25.69, -
17.14) 
-17.26 (-21.20, -
13.32) 
0.54 (0.43, 
0.65) 
0.43 (0.31, 
0.54) 
Neighbourhood 
deprivation quintile 
    
 Least deprived 
Second least deprived 
Mid deprived 
Second most deprived 
Most deprived 
0.0 
2.36 (-2.79, 7.50) 
-0.98 (-6.06, 4.10) 
-2.12 (-7.27, 3.02) 
-13.68 (-18.90, -
8.46) 
0.0 
1.81 (-2.61, 
6.22) 
0.28 (-4.18, 
4.74) 
0.44 (-4.01, 
4.89) 
-7.61 (-12.32, -
2.89) 
0.0 
-0.07 (-0.20, 
0.06) 
-0.02 (-0.14, 
0.11) 
0.03 (-0.10, 
0.15) 
0.32 (0.19, 
0.45) 
0.0 
-0.05 (-0.17, 
0.08) 
-0.02 (-0.14, 
0.11) 
-0.06 (-0.18, 
0.07) 
0.19 (0.06, 
0.32) 
Ethnicity - Caucasian 9.02 (-2.19, 
20.23) 
8.51 (-1.87, 
18.89) 
-0.20 (-0.47, 
0.07) 
-0.13 (-0.42 
,0.17) 
BMI (kg/m2)     
 <25 
25-29.9 
30-34.9 
≥35 
0.0 
4.48 (0.17, 8.78) 
-2.58 (-7.53, 2.38) 
-10.56 (-16.59, -
4.54) 
0.0 
3.19 (-0.53, 
6.93) 
-0.65 (-5.04, 
3.75) 
-6.10 (-11.43, 
0.77) 
0.0 
-0.02 (-0.13, 
0.10) 
0.14 (0.01, 
0.27) 
0.37 (0.21, 
0.52) 
0.0 
-0.01 (-0.12, 
0.10) 
0.06 (-0.07, 
0.18) 
0.21 (0.05, 
0.36) 
Attended further 
education 
9.98 (6.03, 13.93) 5.37 (2.01, 
8.72) 
-0.21 (-0.31, -
0.11) 
-0.09 (-0.19, 
0.01) 
Alcohol intake frequency     
 Daily 
3-4 times per week 
1-2 times per week 
1-3 times per month 
Special occasions 
Never 
0.0 
1.21 (-3.29, 5.70) 
-2.31 (-6.93, 2.32) 
-7.73 (-13.63, -
1.84) 
-19.90 (-25.23, -
14.56) 
-25.91 (-31.81, -
20.02) 
0.0 
1.28 (-2.75, 
5.31) 
-1.48 (-5.62, 
2.67) 
-4.23 (-9.34, 
0.87) 
-9.17 (-14.19, -
4.14) 
-16.10 (-21.63, -
10.57) 
0.0 
-0.07 (-0.18, 
0.04) 
0.06 (-0.06, 
0.17) 
0.17 (0.02, 
0.32) 
0.54 (0.40, 
0.67) 
0.74 (0.6, 0.89) 
0.0 
-0.04 (-0.16, 
0.07) 
-0.01 (-0.12, 
0.11) 
0.09 (-0.06, 
0.23) 
0.26 (0.12, 
0.40) 
0.45 (0.29, 
0.60) 
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 PF-10  (β (95%CI)) HAQ-DI (β (95%CI)) 
Unadjusted Adjusteda Unadjusted Adjusteda 
Not married/cohabiting -10.44 (-14.28, -
6.60) 
-4.76 (-8.23, 
1.30) 
0.25 (0.16, 
0.35) 
0.13 (0.04, 
0.23) 
BMI, Body Mass Index; CI, Confidence Interval; HAQ-DI, Health Assessment Questionnaire Disability 
Index; PF-10, Physical Function 10 
a Adjusted for gout-related and comorbid characteristics 
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Table 5 Linear regression association of HRQOL measured using the Gout Impact Scale with 
sociodemographic characteristics 
 GIS CO (β (95%CI) GIS MSE (β 
(95%CI) 
GIS UTN (β 
(95%CI) 
GIS WBDA (β 
(95%CI) 
GIS CDA (β 
(95%CI) 
Unadjus
ted  
Adjust
ed 
a
 
Unadjus
ted  
Adjust
ed 
a
 
Unadjus
ted  
Adjust
ed 
a
 
Unadjus
ted  
Adjust
ed 
a
 
Unadjus
ted  
Adjust
ed 
a
 
Age -0.56 
(-0.69, -
0.43) 
-0.41 
(-0.57, 
-0.26) 
-0.40 
(-0.52, -
0.28) 
-0.26 
(-0.41, 
-0,10) 
-0.03 
(-0.13, 
0.07) 
-0.04 
(-0.16, 
0.07) 
-0.57 
(-0.69, -
0.45) 
-0.50 
(-0.65, 
-0.35) 
-0.33 
(-0.44, -
0.22) 
-0.24 
(-0.38, 
-0.10) 
Female Gender 1.17 
(-3.31, 
5.65) 
0.86 
(-4.25, 
5.97) 
-1.58 
(-5.80, 
2.65) 
-3.37 
(-8.55, 
1.80) 
3.89 
(0.53, 
7.26) 
1.12 
(-2.78, 
5.03) 
-3.92 
(-8.09, 
0.25) 
-2.87 
(-7.97, 
2.23) 
0.37 
(-3.50, 
4.25) 
2.00 
(-2.61, 
6.62) 
Neighbourhoo
d deprivation 
quintile 
          
 Least 
deprived 
Second 
least 
deprived 
 
Mid 
deprived 
 
Second 
most 
deprived 
 
Most 
deprived 
0.0 
1.57 
(-3.58, 
6.72) 
-0.55 
(-5.66, 
4.55) 
0.95 
(-4.21, 
6.12) 
12.53 
(7.40, 
17.66) 
0.0 
2.48 
(-2.90, 
7.86) 
-1.78 
(-7.18, 
3.62) 
-3.49 
(-8.93, 
1.95) 
2.90 
(-2.61, 
8.42) 
0.0 
-0.84 
(-5.70, 
4.02) 
0.26 
(-4.55, 
5.07) 
0.30 
(-4.58, 
5.17) 
7.66 
(2.82, 
12.49) 
0.0 
-1.70 
(-7.12, 
3.71) 
-2.85 
(-8.29, 
2.59) 
-3.98 
(-9.44, 
1.48) 
-1.36 
(-6.93, 
4.20) 
0.0 
-1.54 
(-5.40, 
2.31) 
-2.30 
(-6.12, 
1.51) 
1.36 
(-2.49, 
5.21) 
3.05 
(-0.78, 
6.88) 
0.0 
0.88 
(-3.21, 
4.98) 
-0.96 
(-5.07, 
3.15) 
0.65 
(-3.47, 
4.77) 
1.70 
(-2.52, 
5.90) 
0.0 
-2.42 
(-7.23, -
2.38) 
-2.58 
(-7.34, 
2.18) 
-2.15 
(-6.95, 
2.65) 
6.59 
(1.79, 
11.38) 
0.0 
-4.59 
(-9.93, 
0.75 
-4.39 
(-9.74, 
0.96) 
-7.56 
(-
12.94, 
-2.17) 
-1.49 
(-6.99, 
4.01) 
0.0 
-0.38 
(-4.80, 
4.04) 
0.37 
(-4.03, 
4.76) 
0.43 
(-4.01, 
4.86) 
11.70 
(7.29, 
16.12) 
0.0 
-0.41 
(-5.23, 
4.41) 
-1.31 
(-6.15, 
3.53) 
-4.57 
(-9.44, 
0.31) 
4.52 
(-0.41, 
9.47) 
Ethnicity - 
Caucasian 
-13.73 
(-24.69, 
-2.77) 
-10.99 
(-
23.71, 
1.74) 
-18.79 
(-28.93, 
-8.64) 
-13.05 
(-
25.73, 
-0.37) 
-7.58 
(-15.59, 
0.43) 
-4.46 
(-
14.02, 
5.09) 
-11.24 
(-21.10, 
-1.38) 
-8.91 
(-
29.11, 
3.29) 
-18.29 
(-27.64, 
-8.93) 
-13.48 
(-
24.81, 
-2.14) 
BMI (kg/m
2
)           
 <25 
25-29.9 
 
30-34.9 
 
≥35 
0.0 
2.97 
(-1.51, 
7.45) 
6.44 
(1.34, 
11.55) 
7.65 
(1.42, 
13.88) 
0.0 
1.71  
(-2.91, 
6.33) 
2.89 
(-2.48, 
8.25) 
4.10 
(-2.51, 
10.70) 
0.0 
1.90 
(-2.28, 
6.07) 
4.66 
(-0.09, 
9.41) 
-5.17 
(-0.61, 
10.95) 
0.0 
-0.78 
(-5.44, 
3.88) 
2.11 
(-3.27, 
7.50) 
-1.23 
(-7.87, 
5.41) 
0.0 
-0.31 
(-3.65, 
3.03) 
0.59 
(-3.20, 
4.38) 
-0.24 
(-4.85, 
4.36) 
0.0 
-0.36 
(-3.86, 
3.14) 
-0.78 
(-4.82, 
3.26) 
-1.84 
(-6.83, 
3.16) 
0.0 
-2.58 
(-6.71, 
1.56) 
2.52 
(-2.18, 
7.23) 
8.69 
(2.91, 
14.47) 
0.0 
-2.81 
(-7.41, 
1.78) 
0.66 
(-4.68, 
6.00) 
2.73 
(-3.91, 
9.37) 
0.0 
1.27 
(-2.56, 
5.10) 
4.57 
(0.22, 
8.92) 
7.89 
(2.58, 
13.20) 
0.0 
-1.83 
(-5.95, 
2.30) 
-0.87 
(-5.66, 
3.92) 
-1.33 
(-4.56, 
7.23) 
Further 
education 
-3.29 
(-7.34, 
0.76) 
2.05 
(-2.08, 
6.19) 
-3.98 
(-7.73, -
0.22) 
1.41 
(-5.57, 
2.75) 
-3.84 
(-6.85, -
0.82) 
-1.57 
(-4.73, 
1.60) 
-2.81 
(-6.58, 
0.95) 
-1.83 
(-5.95, 
2.29) 
-4.94 
(-8.39, -
1.49) 
-3.15 
(-6.84, 
0.54) 
Alcohol 
frequency 
          
 Daily 
3-4 times 
per week 
 
1-2 times 
per week 
 
1-3 times 
0.0 
3.92 
(-0.89, 
8.74) 
6.10 
(1.21, 
10.98) 
1.88 
0.0 
4.55 
(-0.45, 
9.55) 
5.19 
(0.10, 
10.28) 
0.93 
0.0 
4.67 
(0.17, 
9.17) 
3.47 
(-1.10, 
8.03) 
4.16 
0.0 
7.64 
(2.64, 
12.64) 
4.74 
(-0.36, 
9.84) 
5.42 
0.0 
-0.96 
(-4.52, 
2.60) 
2.24 
(-1.36, 
5.85) 
2.24 
0.0 
0.14 
(-3.68, 
3.96) 
-0.01 
(-3.90, 
3.88) 
1.50 
0.0 
2.16 
(-2.34, 
6.66) 
3.82 
(-0.74, 
8.38) 
3.33 
0.0 
4.56 
(-0.40, 
9.52) 
3.99 
(-1.08, 
9.05) 
3.09 
0.0 
2.24 
(-1.88, 
6.37) 
5.75 
(1.55, 
9.96) 
1.54 
0.0 
2.40 
(-2.10, 
6.89) 
-3.15 
(-1.43, 
7.73) 
-0.64 
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 GIS CO (β (95%CI) GIS MSE (β 
(95%CI) 
GIS UTN (β 
(95%CI) 
GIS WBDA (β 
(95%CI) 
GIS CDA (β 
(95%CI) 
Unadjus
ted  
Adjust
ed 
a
 
Unadjus
ted  
Adjust
ed 
a
 
Unadjus
ted  
Adjust
ed 
a
 
Unadjus
ted  
Adjust
ed 
a
 
Unadjus
ted  
Adjust
ed 
a
 
per month 
 
Special 
occasions 
 
Never 
(-4.45, 
8.21) 
5.02 
(-0.63, 
10.67) 
12.17 
(5.88, 
18.46) 
(-5.57, 
7.43) 
-1.75 
(-7.82, 
4.31) 
6.65 
(-0.18, 
13.49) 
(-1.97, 
8.68) 
3.37 
(-1.97, 
8.68) 
10.35 
(4.43, 
16.27) 
(-1.06, 
11.90) 
-1.29 
(-7.37, 
4.80) 
3.52 
(-3.38, 
10.43) 
(-2.40, 
6.87) 
7.39 
(3.19, 
11.58) 
8.10 
(3.43, 
12.77) 
(-3.41, 
6.42) 
5.84 
(1.20, 
10.47) 
2.86 
(-2.37, 
8.09) 
(-2.61, 
9.27) 
1.13 
(-4.13, 
6.39) 
9.55 
(3.71, 
15.39) 
(-3.36, 
9.53) 
-4.87 
(-
10.88, 
1.15) 
4.94 
(-1.84, 
11.71) 
(-3.90, 
6.99) 
4.30 
(-0.56, 
9.15) 
11.55 
(6.17, 
16.94) 
(-6.48, 
5.20) 
-1.21 
(-6.65, 
4.24) 
5.24 
(-0.91, 
11.39) 
Not 
married/cohab
iting 
1.62 
(-2.24, 
5.49) 
-2.13 
(-6.33, 
2.06) 
1.45 
(-2.16, 
5.07) 
-1.90 
(-6.11, 
2.30) 
1.40 
(-1.48, 
4.28) 
-0.55 
(-3.74, 
2.65) 
1.76 
(-1.84, 
5.36) 
-0.21 
(-4.39, 
3.96) 
3.75 
(0.42, 
7.07) 
-0.23 
(-3.99, 
3.53) 
BMI, body mass index; CDA, Concern During Attack; CI, Confidence Interval; CO, Concern Overall; GIS, Gout Impact Scale; 
MSE, Medication Side Effects; UTN, Unmet Treatment Need; WBDA, Wellbeing during attack 
a
 Adjusted for gout-related and comorbid characteristics. 
 
 
 
 
